SAGE Therapeutics (SAGE) Misses Q3 EPS by 9c

SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($2.31), $0.09 worse than the analyst estimate of ($2.22). Revenue for the quarter came in at $1.74 million versus the consensus estimate of $1.68 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal
• CVG to join Russell 2000 and Russell 3000 indexes June 26